Invesco Ltd. Phathom Pharmaceuticals, Inc. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Invesco Ltd. holds 4,096,762 shares of PHAT stock, worth $30.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,096,762

Previous 3,143,452 30.33%

Holding current value

$30.5 Million

Previous $32.4 Million 128.77%

% of portfolio

0.01%

Previous 0.01%

20 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	BUY	$10.25 - $19.5 $9.77 Million - $18.6 Million	953,310 Added 30.33%	4,096,762 $74.1 Million
Q2 2024 Aug 13, 2024	SELL	$8.97 - $12.05 $146,542 - $196,860	-16,337 Reduced 0.52%	3,143,452 $32.4 Million
Q1 2024 May 14, 2024	SELL	$6.21 - $11.05 $48,835 - $86,897	-7,864 Reduced 0.25%	3,159,789 $33.6 Million
Q4 2023 Feb 12, 2024	SELL	$6.99 - $10.71 $1.76 Million - $2.69 Million	-251,306 Reduced 7.35%	3,167,653 $28.9 Million
Q3 2023 Nov 13, 2023	BUY	$10.26 - $15.7 $890,793 - $1.36 Million	86,822 Added 2.61%	3,418,959 $35.5 Million
Q2 2023 Aug 11, 2023	BUY	$7.28 - $14.32 $8.38 Million - $16.5 Million	1,150,465 Added 52.73%	3,332,137 $47.7 Million
Q1 2023 May 12, 2023	SELL	$6.19 - $12.36 $160,797 - $321,075	-25,977 Reduced 1.18%	2,181,672 $15.6 Million
Q4 2022 Feb 13, 2023	BUY	$9.18 - $11.53 $1.28 Million - $1.61 Million	139,781 Added 6.76%	2,207,649 $24.8 Million
Q3 2022 Nov 14, 2022	BUY	$6.46 - $12.11 $136,060 - $255,060	21,062 Added 1.03%	2,067,868 $22.9 Million
Q2 2022 Aug 15, 2022	SELL	$6.2 - $15.5 $18,308 - $45,771	-2,953 Reduced 0.14%	2,046,806 $17.3 Million
Q1 2022 May 16, 2022	SELL	$11.55 - $20.06 $203,245 - $352,995	-17,597 Reduced 0.85%	2,049,759 $27.9 Million
Q4 2021 Feb 14, 2022	BUY	$17.83 - $33.15 $1.27 Million - $2.36 Million	71,340 Added 3.57%	2,067,356 $40.7 Million
Q3 2021 Nov 15, 2021	SELL	$30.69 - $36.83 $779,034 - $934,892	-25,384 Reduced 1.26%	1,996,016 $64.1 Million
Q2 2021 Aug 17, 2021	SELL	$32.66 - $39.87 $245,962 - $300,260	-7,531 Reduced 0.37%	2,021,400 $68.4 Million
Q1 2021 May 17, 2021	SELL	$33.86 - $48.68 $863,667 - $1.24 Million	-25,507 Reduced 1.24%	2,028,931 $76.2 Million
Q4 2020 Feb 16, 2021	SELL	$33.22 - $50.26 $855,381 - $1.29 Million	-25,749 Reduced 1.24%	2,054,438 $68.2 Million
Q3 2020 Nov 16, 2020	SELL	$29.24 - $40.19 $446,085 - $613,138	-15,256 Reduced 0.73%	2,080,187 $76.3 Million
Q2 2020 Aug 14, 2020	BUY	$25.06 - $54.6 $495,135 - $1.08 Million	19,758 Added 0.95%	2,095,443 $69 Million
Q1 2020 May 15, 2020	SELL	$24.65 - $42.83 $656,133 - $1.14 Million	-26,618 Reduced 1.27%	2,075,685 $53.6 Million
Q4 2019 Feb 14, 2020	BUY	$18.59 - $37.67 $39.1 Million - $79.2 Million	2,102,303 New	2,102,303 $65.5 Million

Others Institutions Holding PHAT

# of Institutions

144

Shares Held

73.6M

Call Options Held

42.3K

Put Options Held

45.7K

View Full List

About Phathom Pharmaceuticals, Inc.

Ticker PHAT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,175,200
Market Cap $292M
Description
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...

More about PHAT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account